Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.
Systemic rheumatic diseases, the immunomodulatory medications used to treat them, and the comorbidities associated with them, might predispose individuals to these syndromes. This Series in The Lancet ...
As we enter London Global Cancer Week (Nov 11–15, 2024), cancer care is at a crucial juncture in the UK. Although cancer survival in the UK has improved in the past 50 years, it is still worse than ...